
    
      Subjects in one group will receive MF/IND/GLY together with the Propeller add-on sensor for
      the Breezhaler® and access to the smartphone app according to label. Subjects in the other
      group will receive any triple FDC according to label. The physician's decision to initiate or
      switch a patient to MF/IND/GLY Breezhaler® system or any other triple FDC must have been
      taken prior to and independently from the decision to include the patient in the study.
    
  